A new trading day began on Monday, with Beam Therapeutics Inc (NASDAQ: BEAM) stock price up 3.71% from the previous day of trading, before settling in for the closing price of $21.55. BEAM’s price has ranged from $18.18 to $49.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 43297.50% over the last five years. Meanwhile, its annual earnings per share averaged -172.03%. With a float of $71.66 million, this company’s outstanding shares have now reached $81.63 million.
The firm has a total of 436 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.24%, operating margin of -52.31%, and the pretax margin is -40.16%.
Beam Therapeutics Inc (BEAM) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 13.05%, while institutional ownership is 81.50%. The most recent insider transaction that took place on Oct 14 ’24, was worth 1,342,752. In this transaction President of this company sold 51,110 shares at a rate of $26.27, taking the stock ownership to the 160,260 shares. Before that another transaction happened on Oct 14 ’24, when Company’s Officer proposed sale 102,220 for $24.65, making the entire transaction worth $2,519,723.
Beam Therapeutics Inc (BEAM) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -172.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Here are Beam Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -1.18 in the next quarter and is forecasted to reach -4.64 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Analysing the last 5-days average volume posted by the [Beam Therapeutics Inc, BEAM], we can find that recorded value of 1.16 million was lower than the volume posted last year of 1.23 million. As of the previous 9 days, the stock’s Stochastic %D was 13.71%. Additionally, its Average True Range was 1.22.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 9.38%, which indicates a significant decrease from 19.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.65% in the past 14 days, which was higher than the 61.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.53, while its 200-day Moving Average is $26.80. Now, the first resistance to watch is $22.83. This is followed by the second major resistance level at $23.32. The third major resistance level sits at $23.89. If the price goes on to break the first support level at $21.77, it is likely to go to the next support level at $21.20. Should the price break the second support level, the third support level stands at $20.71.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
With a market capitalization of 1.84 billion, the company has a total of 82,311K Shares Outstanding. Currently, annual sales are 377,710 K while annual income is -132,530 K. The company’s previous quarter sales were 11,770 K while its latest quarter income was -91,050 K.
